{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:23:12Z","timestamp":1770967392025,"version":"3.50.1"},"reference-count":53,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":3294,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:p>Inflammatory conditions decrease the cardiovascular response to calcium channel and \u03b2\u2010adrenergics blockers due, likely, to down\u2010regulation of the receptors mediated by pro\u2010inflammatory mediators such as C\u2010reactive protein (CRP), nitric oxide (NO), and tumor necrosis factor. The purpose of this investigation was to determine whether down\u2010regulation is also evident in angiotensin II type 1 receptors (AT<jats:sub>1<\/jats:sub>R) during varying inflammatory states. Normotensive subjects were divided into three groups according to the severity of disease: 14 with active rheumatoid arthritis, 12 with controlled rheumatoid arthritis, and 12 healthy control subjects. The AT<jats:sub>1<\/jats:sub>R antagonist valsartan (160 mg) was given to all the subjects, and blood samples were taken for pharmacokinetic analysis. The systolic, diastolic, and mean arterial pressures were determined at all blood collection times. The degree of inflammation was measured using joint swelling, NO, and CRP. Plasma valsartan concentration was measured using high\u2010performance liquid chromatography (HPLC). Patients with active disease had significantly higher joint swelling, NO, and CRP than other groups. Plasma valsartan concentration\u2010time curves were remarkably similar in all groups. No reduced response was noticed. Our preliminary observation suggests a need for further studies to examine the possibility of AT1R antagonists as alternatives to other cardiovascular drugs so that their potency may be reduced by inflammation.<\/jats:p>","DOI":"10.1177\/0091270003262951","type":"journal-article","created":{"date-parts":[[2004,2,18]],"date-time":"2004-02-18T23:47:55Z","timestamp":1077148075000},"page":"245-252","source":"Crossref","is-referenced-by-count":20,"title":["Rheumatoid Arthritis Does Not Reduce the Pharmacodynamic Response to Valsartan"],"prefix":"10.1002","volume":"44","author":[{"given":"Noriko","family":"Daneshtalab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Z.","family":"Lewanczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fakhreddin","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.42.10.1078"},{"key":"e_1_2_5_3_2","first-page":"561","article-title":"Study of IL\u20102, IL\u20106, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis","volume":"12","author":"Lepore L","year":"1994","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_4_2","first-page":"230","article-title":"Increased nitric oxide levels in patients with rheumatoid arthritis","volume":"23","author":"Ueki Y","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00380-5"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2001.00743.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(99)00008-X"},{"key":"e_1_2_5_8_2","first-page":"133","article-title":"Review: biology and relevance of C\u2010reactive protein in cardiovascular and renal disease","volume":"30","author":"Westhruyzen J","year":"2000","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331970105200204"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1997.00209.x"},{"key":"e_1_2_5_11_2","first-page":"429","article-title":"High sensitivity C\u2010reactive protein as an independent risk factor for essential hypertension","volume":"16","author":"Sung KC","year":"2003","journal-title":"AJH"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-200207000-00001"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.12.1733"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059040-00002"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.2.92"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6484.1797"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(95)80031-X"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370408"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1987.tb03122.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00314.x"},{"key":"e_1_2_5_21_2","first-page":"240","article-title":"Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen\u2010treated and untreated adjuvant arthritis","volume":"23","author":"Piquette\u2010Miller M","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704067"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10381"},{"key":"e_1_2_5_24_2","first-page":"328","volume-title":"Primer of the Rheumatic Diseases","author":"Schumacher H","year":"1993"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00507-2"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1006\/meth.1995.1004"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/meth.1995.1012"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705202"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00413-3"},{"key":"e_1_2_5_30_2","first-page":"39","article-title":"Diagnostic\u2010therapeutic problems on heart involvement in chronic polyarthritis","volume":"34","author":"Hinz G","year":"1975","journal-title":"Z Rheumatol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.6.640"},{"key":"e_1_2_5_32_2","first-page":"71","article-title":"Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow up study","volume":"27","author":"Wallberg\u2010Jonsson S","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015068"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.17.2107"},{"key":"e_1_2_5_35_2","first-page":"L601","article-title":"Effects of inflammation and acute beta\u2010agonist inhalation on beta 2\u2010AR signaling in human airways","volume":"271","author":"Penn RB","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.85.1.269"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050768"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2002.6524"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1995.0032"},{"key":"e_1_2_5_40_2","unstructured":"SattariS DrydenW JamaliF:The effect of inflammation on the binding of cardioactive agents to rat cardiac cell membrane. Paper presented at the 17th annual meeting of American Association of Pharmaceutical Scientists Toronto Ontario Canada November 1014 2002."},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1999.0951"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.85.3.272"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1997.0458"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000047090.08299.D5"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000061916.95736.E5"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00704-6"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199917040-00012"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0500"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.2.337"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050317"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.14"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90180-6"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.20.2148"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/1043-6618(92)90703-E"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270003262951","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270003262951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:16:10Z","timestamp":1697109370000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270003262951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1177\/0091270003262951"],"URL":"https:\/\/doi.org\/10.1177\/0091270003262951","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}